Business Wire

EVERIMPACT

14.12.2022 16:50:36 CET | Business Wire | Press release

Share
Carbon Monitoring and Monetisation Start-Up Everimpact Closes €1.7M Round

Everimpact, a Climate tech start-up founded by former UN execs and headquartered at Station F (Paris), closes a €1.711M seed funding round backed by leading VCs, corporate ventures and institutions to better measure carbon emissions and allow cities and high emitters to access climate finance to fund impactful climate projects.

The round, led by Motion ventures, includes international organizations, transport companies and impact investors; EU Commission (Climate-Kic and EIT Urban Mobility), Asian Development Bank (ADB Ventures), Transport Companies' VCs and CVCs (Wilhelmsen, Transport Capital, IMC Ventures, MOL PLUS, Blue Star Group) and Impact investors (Rainmaking Impact).

While greenhouse gas emissions (GHG) have been increasingly under scrutiny in the past years, they are mainly self-reported by emitters, based on estimates and updated once a year at best.

Everimpact’s carbon Monitoring, Reporting, and Verification (MRV) platform allows cities and organisations to measure GHG emissions more accurately and in real time, thanks to satellite, ground sensors, and AI data.

Everimpact also certifies carbon emissions and sequestration data to allow cities and industries to better identify reduction opportunities and access carbon finance to fund projects with a demonstrable climate impact.

The start-up is already working with the cities of Dijon (France) with EDF and British cities - in partnership with BT - to monitor and monetise their emissions. Several other cities from the Net Zero City initiative have expressed interest since attracting funding into transport, waste and building decarbonisation is key to successfully implement City Climate contracts. In Japan, Everimpact is partnering with Hitachi Systems to monitor carbon sequestration in municipal forests.

The backing of Everimpact by maritime and supply chain leaders also involves an engineering collaboration aiming at installing its solution onboard vessels to accurately measure their emissions and get access to carbon markets to finance decarbonisation.

This will help the shipping industry accelerate its decarbonisation while complying with significant changes in its environmental regulation such as the Carbon Intensity Indicator rating kicking in 2023 and the inclusion of maritime emissions in the EU Emissions Trading Systems in the next two years.

The funding will be used to expand carbon monitoring and monetisation capabilities in cities at a global level and expand the shipping measurement solution currently trialed on a Mitsubishi Corporation Group vessel and available through an Early Adopter Program.

Mathieu Carlier, CEO and Founder at Everimpact

“Cities and high emitters have a crucial role to play to accelerate the transition to a low carbon world. Thanks to Everimpact's innovative carbon tracking system, they are now able to move away from estimates to monitor their carbon footprint in real time, identify the best opportunities to cut emissions, and access new funding for their decarbonisation projects. We’re excited to partner with leading global organisations and investors to accelerate our development.”

Nicklas Viby Fursund, General Partner of Motion Ventures said: “Bringing together those from the public and private sector with the most influence on maritime and global supply chains is unprecedented. The pairing of the engineering collaboration and strategic capital is not just a milestone for Everimpact but a proof point for a consortium approach to innovation.”

About Everimpact

Everimpact helps cities and businesses accurately measure their greenhouse gas emissions, identify opportunities to reduce emissions, and finance required investments through the carbon markets.

While most cities and businesses report GHG emissions based on estimates, Everimpact IoT software combines satellite, ground sensors, and AI data to precisely measure emissions in real-time.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005661/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye